Buspirone in Parkinson's Disease

Exclusion Criteria

• •Diagnosis of atypical or secondary parkinsonism
• •Concomitant treatment with an MAO inhibitor within the 14 days prior to screening visit
• •Significant renal or hepatic impairment
• •Significant cognitive impairment defined as MOCA score \< 23
• •On-going depression with suicidal or homicidal ideation and concern for patient safety based on clinical determination by the investigator
• •Allergy or intolerance to study drug, matching placebo, or their formulations
• •History of prior exposure to study drug
• •Lactating or pregnant woman
• •Concomitant treatment with a disallowed medication (detailed in section 6.2)
• •Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements
• •Concomitant treatment with an anxiolytic or antidepressant will be allowed however potential participants who had dosage changes in the 30 days prior to the screening visit will be excluded
• •Use of an investigational drug within 30 days prior to screening visit
• •Any medical or psychiatric comorbidity that, in the opinion of the investigator, would compromise study participation
• •Dysphagia defined as a score of ≥ 2 on MDS-UPDRS Item 2.3 Chewing and Swallowing